PUBLIC COMPANY
saveInnovent Biologics Inc
updated 3mo ago
Innovent Biologics, Inc. is a publicly listed Chinese biopharmaceutical company that is headquartered in Suzhou, Jiangsu.
community read0 votes
🐶 often sniffed alongside
top 3pipeline
5
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(5)
pipeline depth5 products
2Phase 12Phase 21Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- J&J bets $2.2B on Ollin’s vision loss drugThe deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.biopharma_dive · 7h ago
- J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trialBlackstone will provide $750 million for Phase 3 development of Ollin Biosciences’ retinal disease bispecific as Johnson & Johnson looks to bolster its eye therapeutics pipeline after several setba…biospace · 9h ago
- J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecificJohnson & Johnson has struck a deal to buy Ollin Biosciences for $2.2 billion upfront, establishing itself as a threat to Roche’s blockbuster eye disease drug Vabysmo.fiercebiotech · 15h ago
- Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think soFor executives at many of the Chinese drug developers who spoke to Fierce, the real prize is a seat at the Big Pharma table. In recent years, this objective has moved from a vague aspiration to a c…fiercebiotech · 9d ago
- At ASH, drugmakers to showcase early data for three-pronged cancer therapiesJ&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment for multiple myeloma.biopharma_dive · 11d ago
- ESMO: Takeda’s $1.2B bet on Innovent ‘absolutely’ pays off with details of ADC’s phase 3 winTakeda has lifted the lid on the phase 3 win for its next-generation claudin18.2 drug, with the antibody-drug conjugate (ADC) demonstrating overall survival of 10.2 months.fiercebiotech · 24d ago
- Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing dealsDespite the sweeping scope of the ban covering various types of drug molecules, biopharma business development teams can breathe a measured sigh of relief.fiercebiotech · 25d ago
- Lilly’s latest China drug deal; Immunovant’s setback in lupusLilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded a…biopharma_dive · 1mo ago
- China poses increasing security risk as US biotech innovation edge erodesThe U.S. is scrambling to compete with a strategically positioned China on the biotech stage as the Asian country surpasses America in biomedical research and clinical trials. So far, China is winn…biospace · 2mo ago
- RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 winPlus news about Avere Therapeutics, Novo Nordisk, Sobi, Innate Pharma, Oculis, Innovent Biologics and Daiichi Sankyo. 🌏 BeOne gets rights to RevMed drugs in 'select Asian markets': The deal includ…endpoints · 3mo ago
comments(0)
5-min edit window · permanent after that